Review
Version 1
Preserved in Portico This version is not peer-reviewed
Stereotactic Body Radiotherapy Immunological Planning – Road to Abscopal Effect by Design
Version 1
: Received: 4 June 2021 / Approved: 7 June 2021 / Online: 7 June 2021 (09:32:33 CEST)
A peer-reviewed article of this Preprint also exists.
Swamy, K. Stereotactic Body Radiotherapy Immunological Planning—A Review With a Proposed Theoretical Model. Frontiers in Oncology 2022, 12, doi:10.3389/fonc.2022.729250. Swamy, K. Stereotactic Body Radiotherapy Immunological Planning—A Review With a Proposed Theoretical Model. Frontiers in Oncology 2022, 12, doi:10.3389/fonc.2022.729250.
Abstract
This review highlights normal and tumor tissue vasculature, immunological changes, and phenotypic alterations (VIP model) as fundamental in abscopal interaction. In the stereotactic body radiotherapy (SBRT) and immunotherapy era, we are moving toward “immunological radiation planning,” i.e., radiation scheduling with abscopal effect as a vital endpoint as well. Towards this end, this manuscript presents specific diagrammatic tumor models to optimize the outcome of abscopal response in SBRT, based on the principle of the four R’s - Repair, Redistribution, Repopulation, and Reoxygenation of radiotherapy. The article highlights the importance of restricting the dose of SBRT to < 10 Gy per fraction, appropriate use of dose painting, and concomitant/delayed SBRT boost potential. Current literature indicates that immunotherapy should not precede but follow SBRT within seven days. Included is the review of integrating “cyclical” antiangiogenics, immune adjuvants/immune-metabolites as abscopal effect enhancers with SBRT. The importance of proton, carbon-ion SBRT is dealt with briefly. Proposed six fundamental requirements for augmentation of the abscopal cascade are listed. The existing exploratory results need to develop a definitive strategy amidst complex interactions in SBRT, immunotherapy, immune-adjuvants, & abscopal effects. We now have enough literature evidence to convert “abscopal by chance” to “abscopal by design” by harmonized combinatorial approach.
Keywords
SBRT; SABR; Abscopal; vascular-normalization; immunotherapy; phenotypic; antiangiogenics; immunoadjuvants; VIP-model; High-LET
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment